The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1521
May 22, 2017
View Complete Issue         Table of Contents 2019 
Valbenazine (Ingrezza) for Tardive Dyskinesia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Valbenazine (Ingrezza) for Tardive Dyskinesia
May 22, 2017 (Issue: 1521)
The FDA has approved valbenazine (Ingrezza – Neurocrine Biosciences), a vesicular monoamine transporter 2 (VMAT2) inhibitor, for treatment of tardive dyskinesia in adults. It is the first drug to be approved in the US for this indication; two...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Valbenazine (Ingrezza) for Tardive Dyskinesia
Article code: 1521b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.